Illumina's revenue has grown by 6.0% a year over the last 5 years – slower than the median of the Health Care sector (+8.5%). The net margin in the last fiscal year was 19.6%, the sector median 13.9%. The 52-week high is 60.4% away (close of Nov 20, 2026).
Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Academy: 200-day line · RSI
About the company
Illumina is a US maker of gene sequencing technology. The company sells instruments and consumables that labs use to read genetic material, for example for research, cancer diagnostics and prenatal testing. Customers are universities, hospitals and pharmaceutical companies. As of Oct 13, 2026
As of Oct 13, 2026Fact sheet (from the annual report)Laboratory instruments · San Diego, USAfull fact sheet
Illumina develops sequencing and array-based solutions that can be used to analyze genetic material. The company was founded in California in 1998, has been incorporated in Delaware since 2000 and is headquartered in San Diego. Its customers include genome research centers, universities, government labs and hospitals as well as pharmaceutical and biotech companies, diagnostic labs and consumer genetic testing providers. In 2025 most of the revenue came from consumables such as reagents and flow cells, and the rest from instruments as well as services and other. Illumina sells directly in North America, Europe, Latin America and the Asia-Pacific region, and in some markets also through distributors.
This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.
Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze
Price performance at a glance
Last 30 trading days
Today−3.9%
7 days−6.9%
30 days−31.8%
1 year+61.7%
Day range (last trading day)
−0.8%Price at 20% of the range+3.3%
52-week range
−41.6%Price at 41% of the range+60.4%
Distance from the all-time high
−64.3%
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Chart analysis: trend by timeframe
Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure
1Wweekly candles↗ up
Close above the SMA 200
EMA 20 above the EMA 50
higher highs and higher lows
Price below the EMA 20 · above the EMA 50
Week to Nov 20, 2026
1Ddaily candles↔ mixed
Close above the SMA 200
EMA 20 below the EMA 50
lower highs and lower lows
Price below the EMA 20 · below the EMA 50
Daily candle of Nov 20, 2026
4H4-hour candles– not available
No value on 4 hours (too few or no checked 4-hour candles).
Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up →
What does the daily chart show right now – line by line, without an overall verdict?
Technicals in plain words
Technicals in plain wordsFour lines on the daily chart – trend, momentum, volume, volatility –, each with its metric and threshold. We do not add the lines up or give a grade; they describe the price history so far.Example: RSI 64 → between 30 and 70, neither overbought nor oversold.More in the Academy: Lesson reading the RSI
Over the last 3 months it ran weaker than the S&P 500 and weaker than the median of the sector “Health Care”.
vs. S&P 500 · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
weaker
vs. S&P 500 · 6 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. sector · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
weaker
Trendabove SMA 200Price above the 200-day line – above it the long-term trend counts as up; ADX above 25 – a pronounced trend.
MomentumneutralRSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
Volumenot elevatedVolume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
VolatilityhighTypical daily range (ATR 14) above 4% of the price – high.
The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account.Sign up free
More depth
How we read the lines
Each line stands on its own – we do not add them up and give no grade.
Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
Against the sector median over 6 months: ran stronger.
All figures describe the price history so far – they do not say what happens next.
As of: daily candle of Nov 20, 2026 · from our daily candles
How did this asset do in each calendar month over the last 10 years?
Seasonality
SeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
In November, the stock closed higher in 5 of 10 years – the S&P 500 in 9 of 10.
Years higher in NovemberSeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
5 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
4 of 12
Calendar months that closed higher in more than half of the years
You can see the median and range per month in percent with a free account.Sign up free
6/10Jan
3/10Feb
5/10Mar
6/10Apr
5/10May
7/10Jun
9/10Jul
4/10Aug
3/10Sep
5/10Oct
5/10Nov
4/10Dec
January: higher in 6 of 10 years
February: higher in 3 of 10 years
March: higher in 5 of 10 years
April: higher in 6 of 10 years
May: higher in 5 of 10 years
June: higher in 7 of 10 years
July: higher in 9 of 10 years
August: higher in 4 of 10 years
September: higher in 3 of 10 years
October: higher in 5 of 10 years
November (current month): higher in 5 of 10 years
December: higher in 4 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividendsMore depth
How we calculate
Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
Month
Years higher
January
6 of 10
February
3 of 10
March
5 of 10
April
6 of 10
May
5 of 10
June
7 of 10
July
9 of 10
August
4 of 10
September
3 of 10
October
5 of 10
November ●
5 of 10
December
4 of 10
Through October 2026 (last completed month) · from our daily candles
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Illumina, Inc. · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 12, 2026.
Investor typeInvestor type (“lens”)You choose which style comes first: dividends, valuation, growth, quality or trading. Screener and stock page then show suggestions and “For you first”, with an account also matching columns and order. The lens unlocks nothing and changes no matches.Example: Lens “Dividends” → on the stock page first the streak without a cut, growth and cover of the dividend.More in the Academy: Guide fundamental analysis
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
✗not met: Profit in each of the last 5 fiscal years2 of 5
✓met: Free cash flow positive in each of the last 3 fiscal years3 of 3
✓met: Equity ratio above 30%41.0%
Gross margin
66.1%Fiscal year 2025
All77strong
Rank 77 of 100: higher than 77% of 370 peers (All). strong.
Sector62medium
Rank 62 of 100: higher than 62% of 49 peers (Sector). medium.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Operating margin
18.6%Fiscal year 2025
All58medium
Rank 58 of 100: higher than 58% of 470 peers (All). medium.
Sector62medium
Rank 62 of 100: higher than 62% of 54 peers (Sector). medium.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
19.6%Fiscal year 2025
All76strong
Rank 76 of 100: higher than 76% of 584 peers (All). strong.
Sector74strong
Rank 74 of 100: higher than 74% of 63 peers (Sector). strong.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
31.2%Fiscal year 2025
All81strong
Rank 81 of 100: higher than 81% of 544 peers (All). strong.
Sector84strong
Rank 84 of 100: higher than 84% of 54 peers (Sector). strong.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
Return on assets
12.8%Fiscal year 2025 (total assets at year end)
All84strong
Rank 84 of 100: higher than 84% of 594 peers (All). strong.
Sector79strong
Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
Equity ratio
41.0%Fiscal year 2025
All57medium
Rank 57 of 100: higher than 57% of 595 peers (All). medium.
Sector45medium
Rank 45 of 100: higher than 45% of 63 peers (Sector). medium.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
21.4%Fiscal year 2025
All80strong
Rank 80 of 100: higher than 80% of 465 peers (All). strong.
Sector76strong
Rank 76 of 100: higher than 76% of 61 peers (Sector). strong.
Median Health Care: 14.5%
Free cash flow divided by revenue.
Free cash flow
931.0M USDFiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 2 of 6 met · 1 without data
✗not met: Over 3 years, revenue grew by more than 5% per year−1.8%
✓met: Over 5 years, revenue grew by more than 5% per year+6.0%
✓met: Over 10 years, revenue grew by more than 5% per year+6.9%
–no data: Over 3 years, EPS grew by more than 5% per yearnot computable (loss in the first year, or figures missing)
✗not met: Over 5 years, EPS grew by more than 5% per year+4.1%
✗not met: Revenue rose in at least 4 of the last 5 fiscal years2 of 5
✗not met: Revenue rose in the last fiscal year−0.7%
Revenue growth 3 years
−1.8%per year
All16weak
Rank 16 of 100: higher than 16% of 578 peers (All). weak.
Sector14weak
Rank 14 of 100: higher than 14% of 62 peers (Sector). weak.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+6.0%per year
All34medium
Rank 34 of 100: higher than 34% of 549 peers (All). medium.
Sector36medium
Rank 36 of 100: higher than 36% of 60 peers (Sector). medium.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+6.9%per year
All55medium
Rank 55 of 100: higher than 55% of 412 peers (All). medium.
Sector29weak
Rank 29 of 100: higher than 29% of 50 peers (Sector). weak.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
EPS growth 5 years
+4.1%per year
All25weak
Rank 25 of 100: higher than 25% of 399 peers (All). weak.
Sector33medium
Rank 33 of 100: higher than 33% of 47 peers (Sector). medium.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
+5.8%per year
All33medium
Rank 33 of 100: higher than 33% of 375 peers (All). medium.
Sector34medium
Rank 34 of 100: higher than 34% of 46 peers (Sector). medium.
Median Health Care: +9.3%
Growth of earnings per share per year, adjusted for stock splits.
Dividend 0 of 1 met · 6 without data
✗not met: Pays a dividendno dividend per share reported for the last fiscal year
–no data: Payout ratio at most 60% of earningspays no dividend
–no data: Dividend paid in each of the last 5 fiscal yearspays no dividend
–no data: Dividend per share never lowered in the last 5 fiscal yearspays no dividend
–no data: Dividend per share higher than 5 years agopays no dividend
–no data: Free cash flow per share covers the dividendpays no dividend
–no data: Dividends paid over the last 5 years covered by free cash flowpays no dividend
Financial strength 5 of 6 met
✓met: Piotroski F-Score at least 7 of 99 of 9
✓met: Long-term debt no higher than equity0.55
✓met: Current assets cover current liabilities2.08
✓met: Positive equity2.7B USD
✗not met: In 5 years, share count up by at most 5%+5.4%
✓met: Free cash flow positive in the last fiscal year931.0M USD
Piotroski F-Score
9 of 9Fiscal year 2025
All98strong
Rank 98 of 100: higher than 98% of 310 peers (All). strong.
Sector96strong
Rank 96 of 100: higher than 96% of 47 peers (Sector). strong.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.55at fiscal year end
All57medium
Rank 57 of 100: lower than 57% of 486 peers (All). medium.
Sector57medium
Rank 57 of 100: lower than 57% of 50 peers (Sector). medium.
Median Health Care: 0.66
Long-term financial debt divided by equity.
Liquidity (current ratio)
2.08at fiscal year end
All75strong
Rank 75 of 100: higher than 75% of 513 peers (All). strong.
Sector69strong
Rank 69 of 100: higher than 69% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
Change in share count
+5.4%in 5 years
All25weak
Rank 25 of 100: lower than 25% of 507 peers (All). weak.
Sector11weak
Rank 11 of 100: lower than 11% of 59 peers (Sector). weak.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
✓met: Profit in the last fiscal year (positive return on assets)
✓met: Positive operating cash flow
✓met: Return on assets higher than the prior year
✓met: Operating cash flow higher than net income
✓met: Long-term debt relative to total assets fell
✓met: Liquidity (current assets / current liabilities) rose
✓met: No additional shares (diluted share count did not rise)
✓met: Gross margin higher than the prior year
✓met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
Light yellow: Revenue grew over 5 years (+6.0% per year), more slowly than the sector median.
Light yellow: Net income (total) grew over 5 years (+5.3% per year), more slowly than the sector median; per share +4.1% per year.
Light green: Net margin 19.6%, above the sector median (13.9%).
Light green: Debt not higher than usual in the sector.
Light red: Profit in 7 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
−5B−2.5B02.5B5B
2016Fiscal year 2016 (Jan 4, 2016 – Jan 1, 2017): Revenue 2.4B USD · Net income 462.6M USD · Net margin 19.3%
2017Fiscal year 2017 (Jan 2, 2017 – Dec 31, 2017): Revenue 2.8B USD · Net income 726.0M USD · Net margin 26.4%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 30, 2018): Revenue 3.3B USD · Net income 826.0M USD · Net margin 24.8%
2019Fiscal year 2019 (Dec 31, 2018 – Dec 29, 2019): Revenue 3.5B USD · Net income 1.0B USD · Net margin 28.3%
2020Fiscal year 2020 (Dec 30, 2019 – Jan 3, 2021): Revenue 3.2B USD · Net income 656.0M USD · Net margin 20.3%
2021Fiscal year 2021 (Jan 4, 2021 – Jan 2, 2022): Revenue 4.5B USD · Net income 762.0M USD · Net margin 16.8%
2022Fiscal year 2022 (Jan 3, 2022 – Jan 1, 2023): Revenue 4.6B USD · Net income −4.4B USD · Net margin −96.1%
2023Fiscal year 2023 (Jan 2, 2023 – Dec 31, 2023): Revenue 4.5B USD · Net income −1.2B USD · Net margin −25.8%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 29, 2024): Revenue 4.4B USD · Net income −1.2B USD · Net margin −28.0%
2025Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 4.3B USD · Net income 850.0M USD · Net margin 19.6%
Margin
19%26%25%28%20%17%−96%−26%−28%20%
RevenueNet incomeNet margin (below)in USD
−2B−1B01B2B
Q4/23Quarter Q4/23 (Oct 2, 2023 – Dec 31, 2023): Revenue 1.1B USD · Net income −176.0M USD · Net margin −15.7% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 1.1B USD · Net income −126.0M USD · Net margin −11.7%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 1.1B USD · Net income −2.0B USD · Net margin −178.8%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 29, 2024): Revenue 1.1B USD · Net income 705.0M USD · Net margin 65.3%
Q4/24Quarter Q4/24 (Sep 30, 2024 – Dec 29, 2024): Revenue 1.1B USD · Net income 186.0M USD · Net margin 16.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Dec 30, 2024 – Mar 30, 2025): Revenue 1.0B USD · Net income 131.0M USD · Net margin 12.6%
Q2/25Quarter Q2/25 (Mar 31, 2025 – Jun 29, 2025): Revenue 1.1B USD · Net income 235.0M USD · Net margin 22.2%
Q3/25Quarter Q3/25 (Jun 30, 2025 – Sep 28, 2025): Revenue 1.1B USD · Net income 150.0M USD · Net margin 13.8%
Q4/25Quarter Q4/25 (Sep 29, 2025 – Dec 28, 2025): Revenue 1.2B USD · Net income 334.0M USD · Net margin 28.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Dec 29, 2025 – Mar 29, 2026): Revenue 1.1B USD · Net income 134.0M USD · Net margin 12.3%
Q2/26Quarter Q2/26 (Mar 30, 2026 – Jun 28, 2026): Revenue 1.2B USD · Net income 207.0M USD · Net margin 17.9%
Q3/26Quarter Q3/26 (Jun 29, 2026 – Sep 27, 2026): Revenue 1.1B USD · Net income 220.0M USD · Net margin 19.5%
Margin
−16%−12%−179%65%17%13%22%14%29%12%18%19%
Earnings per shareUSD per share
−30−20−10010
2016Fiscal year 2016 (Jan 4, 2016 – Jan 1, 2017): Earnings per share 3.07 USD
2017Fiscal year 2017 (Jan 2, 2017 – Dec 31, 2017): Earnings per share 4.92 USD
2018Fiscal year 2018 (Jan 1, 2018 – Dec 30, 2018): Earnings per share 5.56 USD
2019Fiscal year 2019 (Dec 31, 2018 – Dec 29, 2019): Earnings per share 6.74 USD
2020Fiscal year 2020 (Dec 30, 2019 – Jan 3, 2021): Earnings per share 4.45 USD
2021Fiscal year 2021 (Jan 4, 2021 – Jan 2, 2022): Earnings per share 5.04 USD
2022Fiscal year 2022 (Jan 3, 2022 – Jan 1, 2023): Earnings per share −28.00 USD
2023Fiscal year 2023 (Jan 2, 2023 – Dec 31, 2023): Earnings per share −7.34 USD
2024Fiscal year 2024 (Jan 1, 2024 – Dec 29, 2024): Earnings per share −7.69 USD
2025Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Earnings per share 5.45 USD
Earnings per shareUSD per share
−15−10−5.0005.00
Q4/23Quarter Q4/23 (Oct 2, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share −0.79 USD
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share −12.48 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 4.3B USD · Net income 850.0M USD · Net margin 19.6%
How has it gone since the last annual report?
Trailing 12 months and quarters
Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Revenue in the quarter to Sep 2026 +4.2% vs. the same quarter a year earlier; grown for 5 quarters in a row.
Revenue 12 months vs. prior 12Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Free cash flow margin 12 monthsFree cash flowCash from operations minus investment in property, plant and equipment. It shows how much money is left over – for repaying debt, dividends or share repurchases.Example: Operating cash flow 120 million euros, investments 45 million euros → free cash flow 75 million euros.More in the Academy: Guide fundamental analysis
23.3%
Fiscal year 2025: 21.4%
More depth
Calculation of the 12 months to Sep 27, 2026
Revenue: fiscal year to Dec 28, 2025 4.3B USD + year to date to Sep 27, 2026 3.4B USD − same period a year earlier to Sep 28, 2025 3.2B USD = 4.5B USD
Net income: fiscal year to Dec 28, 2025 850.0M USD + year to date to Sep 27, 2026 561.0M USD − same period a year earlier to Sep 28, 2025 516.0M USD = 895.0M USD
Operating cash flow: fiscal year to Dec 28, 2025 1.1B USD + year to date to Sep 27, 2026 909.0M USD − same period a year earlier to Sep 28, 2025 758.0M USD = 1.2B USD
Capital expenditure: fiscal year to Dec 28, 2025 148.0M USD + year to date to Sep 27, 2026 118.0M USD − same period a year earlier to Sep 28, 2025 93.0M USD = 173.0M USD
By quarter (latest first, amounts in USD)
Quarter
Revenue
vs. year ago
Net income
Margin
Jul–Sep 26
1.1B
+4.2%
220.0M
19.5%
Apr–Jun 26
1.2B
+9.4%
207.0M
17.9%
Jan–Mar 26
1.1B
+4.8%
134.0M
12.3%
Oct–Dec 25*
1.2B
+5.0%
334.0M
28.8%
Jul–Sep 25
1.1B
+0.4%
150.0M
13.8%
Apr–Jun 25
1.1B
−4.8%
235.0M
22.2%
Jan–Mar 25
1.0B
−3.3%
131.0M
12.6%
Oct–Dec 24*
1.1B
−1.6%
186.0M
16.8%
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 27, 2026, filed on Oct 30, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Earnings quality
Profit is backed by cash; interest is well covered.
Cash flow ÷ profitCash flow ÷ profitOperating cash flow divided by group profit. From 1.0, at least as much cash came in as profit was reported; below that, profit may sit in receivables or inventories, and non-cash gains or one-off payments also push the ratio down. Depreciation and stock-based pay lift it.Example: Operating cash flow €120m, group profit €100m → 1.20x.More in the Academy: Lesson earnings quality
1.27x
0.81.0
backed from 1.0
Interest coverageInterest coverageOperating income divided by interest expense: how many times the core business earns its interest. From 5x we count interest as well covered, below 2x as thinly covered.Example: Operating income €50m, interest expense €5m → 10.0x.More in the Academy: Lesson earnings quality
8.0x
25
well covered from 5 · 3 years: negative
Tax rateTax rateIncome taxes divided by profit before tax, in percent. If the SEC data lack it, we approximate it as group profit plus taxes; minority interests, discontinued operations, one-off items and tax credits can shift the rate.Example: Taxes €21m, net income €79m → 21 : 100 = 21%.More in the Academy: Lesson earnings quality
21.7%
for information only
More depth
Calculation for fiscal year 2025
Operating cash flow 1.1B USD ÷ Net income 850.0M USD = 1.27x
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
Consistency
In 10 fiscal years 3 loss years and 4 years with lower revenue.
Loss yearsLoss yearsFiscal years that ended with a loss on the bottom line (net income below zero). Few loss years over a long period show how evenly a company has earned so far – they say nothing about the future.Example: Loss only in fiscal year 2020 → 1 of 10.More in the Academy: Lesson revenue, profit and margin
3 of 10
net income below zero
Years with lower revenueYear with lower revenueA fiscal year in which revenue was lower than in the prior year. Only years for which the prior year’s revenue is also reported are counted.Example: Revenue 100 → €96m → one year with lower revenue.More in the Academy: Lesson revenue, profit and margin
4 of 10
revenue below the prior year
Net margin rangeNet margin rangeHighest minus lowest net margin of the fiscal years shown, in percentage points. A small range means the share of profit in revenue stayed similar over the years.Example: Net margins between 18.2% and 26.4% → range 8.2 percentage points.More in the Academy: Lesson revenue, profit and margin
124.4 percentage points
from −96.1% to 28.3%
▾▾▾▾20162025Net margin by fiscal year · ▾ revenue below the prior yearMore depth
By fiscal year
FY
Revenue vs. prior year
Net margin
2025
−0.7%
19.6%
2024
−2.9%
−28.0%
2023
−1.7%
−25.8%
2022
+1.3%
−96.1%
2021
+39.7%
16.8%
2020
−8.6%
20.3%
2019
+6.3%
28.3%
2018
+21.1%
24.8%
2017
+14.8%
26.4%
2016
+8.0%
19.3%
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 66.1 USD gross profit, 18.6 USD operating income and 19.6 USD net income remained.
Net income is above operating income (e.g. a tax benefit, gains on investments or securities).
Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
Item
Amount
of revenue
Revenue
4.3B USD
100.0%
Gross profit
2.9B USD
66.1%
Cost of revenue
1.5B USD
33.9%
Operating income
807.0M USD
18.6%
Research & development
967.0M USD
22.3%
Other operating expenses
1.1B USD
25.2%
Net income
850.0M USD
19.6%
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin stayed roughly the same in 5 years (18.6%).
Gross marginOperating marginNet margin
−100%−50%0%50%100%
2016Fiscal year 2016: Gross margin 69.5% · Operating margin 24.5% · Net margin 19.3%
2017Fiscal year 2017: Gross margin 66.4% · Operating margin 22.0% · Net margin 26.4%
2018Fiscal year 2018: Gross margin 69.0% · Operating margin 26.5% · Net margin 24.8%
2019Fiscal year 2019: Gross margin 69.6% · Operating margin 27.8% · Net margin 28.3%
2020Fiscal year 2020: Gross margin 68.0% · Operating margin 17.9% · Net margin 20.3%
2021Fiscal year 2021: Gross margin 69.7% · Operating margin −2.7% · Net margin 16.8%
2022Fiscal year 2022: Gross margin 64.8% · Operating margin −91.2% · Net margin −96.1%
2023Fiscal year 2023: Gross margin 60.9% · Operating margin −23.7% · Net margin −25.8%
2024Fiscal year 2024: Gross margin 65.4% · Operating margin −19.1% · Net margin −28.0%
2025Fiscal year 2025: Gross margin 66.1% · Operating margin 18.6% · Net margin 19.6%
Returns
Return on equity rose in 5 years from 14.0% to 31.2%.
Return on equityReturn on assets
−75%−50%−25%0%25%50%
2016Fiscal year 2016: Return on equity 21.1% · Return on assets 10.8%
2017Fiscal year 2017: Return on equity 26.4% · Return on assets 13.8%
2018Fiscal year 2018: Return on equity 22.0% · Return on assets 11.9%
2019Fiscal year 2019: Return on equity 21.7% · Return on assets 13.7%
2020Fiscal year 2020: Return on equity 14.0% · Return on assets 8.6%
2021Fiscal year 2021: Return on equity 7.1% · Return on assets 5.0%
2022Fiscal year 2022: Return on equity −66.7% · Return on assets −35.9%
2023Fiscal year 2023: Return on equity −20.2% · Return on assets −11.5%
2024Fiscal year 2024: Return on equity −51.5% · Return on assets −19.4%
2025Fiscal year 2025: Return on equity 31.2% · Return on assets 12.8%
Equity and long-term debt
The equity ratio fell in 5 years from 61.9% to 41.0%.
EquityLong-term debtin USDLong-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.
2016Fiscal year 2016: Operating cash flow 687.2M USD · Capital expenditure 259.9M USD · Free cash flow 427.3M USD
2017Fiscal year 2017: Operating cash flow 875.0M USD · Capital expenditure 310.0M USD · Free cash flow 565.0M USD
2018Fiscal year 2018: Operating cash flow 1.1B USD · Capital expenditure 296.0M USD · Free cash flow 846.0M USD
2019Fiscal year 2019: Operating cash flow 1.1B USD · Capital expenditure 209.0M USD · Free cash flow 842.0M USD
2020Fiscal year 2020: Operating cash flow 1.1B USD · Capital expenditure 189.0M USD · Free cash flow 891.0M USD
2021Fiscal year 2021: Operating cash flow 545.0M USD · Capital expenditure 208.0M USD · Free cash flow 337.0M USD
2022Fiscal year 2022: Operating cash flow 392.0M USD · Capital expenditure 286.0M USD · Free cash flow 106.0M USD
2023Fiscal year 2023: Operating cash flow 478.0M USD · Capital expenditure 195.0M USD · Free cash flow 283.0M USD
2024Fiscal year 2024: Operating cash flow 837.0M USD · Capital expenditure 128.0M USD · Free cash flow 709.0M USD
2025Fiscal year 2025: Operating cash flow 1.1B USD · Capital expenditure 148.0M USD · Free cash flow 931.0M USD
Share count
The share count rose in 5 years by 5.4% – more new shares were issued than repurchased (dilution).
Diluted share count
050M100M150M200M
2016Fiscal year 2016: Diluted share count 148.0M
2017Fiscal year 2017: Diluted share count 148.0M
2018Fiscal year 2018: Diluted share count 149.0M
2019Fiscal year 2019: Diluted share count 149.0M
2020Fiscal year 2020: Diluted share count 148.0M
2021Fiscal year 2021: Diluted share count 151.0M
2022Fiscal year 2022: Diluted share count 157.0M
2023Fiscal year 2023: Diluted share count 158.0M
2024Fiscal year 2024: Diluted share count 159.0M
2025Fiscal year 2025: Diluted share count 156.0M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Metrics chart
Metrics chartUp to three metrics stacked, each with its own axis, over the same fiscal years. Optionally a second stock (dashed or hatched) and today’s sector median as a mark in the latest year – we do not have earlier medians.Example: Revenue rises, net margin falls, share count falls → more business, less profit per unit of revenue, fewer shares (mostly through buybacks).More in the Academy: Guide fundamental analysis
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Revenue
Revenue rose in 5 years from 3.2B USD to 4.3B USD.
ILMNin USD
02B4B6B
2016Fiscal year 2016: ILMN 2.4B USD
2017Fiscal year 2017: ILMN 2.8B USD
2018Fiscal year 2018: ILMN 3.3B USD
2019Fiscal year 2019: ILMN 3.5B USD
2020Fiscal year 2020: ILMN 3.2B USD
2021Fiscal year 2021: ILMN 4.5B USD
2022Fiscal year 2022: ILMN 4.6B USD
2023Fiscal year 2023: ILMN 4.5B USD
2024Fiscal year 2024: ILMN 4.4B USD
2025Fiscal year 2025: ILMN 4.3B USD
Net margin
The net margin stayed roughly the same in 5 years (19.6%).
ILMNSector today 14.6%Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
−100%−50%0%50%
2016Fiscal year 2016: ILMN 19.3%
2017Fiscal year 2017: ILMN 26.4%
2018Fiscal year 2018: ILMN 24.8%
2019Fiscal year 2019: ILMN 28.3%
2020Fiscal year 2020: ILMN 20.3%
2021Fiscal year 2021: ILMN 16.8%
2022Fiscal year 2022: ILMN −96.1%
2023Fiscal year 2023: ILMN −25.8%
2024Fiscal year 2024: ILMN −28.0%
2025Fiscal year 2025: ILMN 19.6% · Sector today 14.6%
Free cash flow margin
The free cash flow margin fell in 5 years from 27.5% to 21.4%.
ILMNSector today 15.8%
0%10%20%30%
2016Fiscal year 2016: ILMN 17.8%
2017Fiscal year 2017: ILMN 20.5%
2018Fiscal year 2018: ILMN 25.4%
2019Fiscal year 2019: ILMN 23.8%
2020Fiscal year 2020: ILMN 27.5%
2021Fiscal year 2021: ILMN 7.4%
2022Fiscal year 2022: ILMN 2.3%
2023Fiscal year 2023: ILMN 6.3%
2024Fiscal year 2024: ILMN 16.2%
2025Fiscal year 2025: ILMN 21.4% · Sector today 15.8%
Source: SEC filings, fiscal years up to Dec 28, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
Dividend at a glance
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
Valuation against its own history
Valuation against its own historyWhere P/E, P/S or price/free cash flow stands today compared with the median of the company’s own last 5 fiscal years, in percent. Up to 10% deviation counts as “about at the median”. Describes only the position, not a judgement on an appropriate price.Example: P/E today 22, own 5-year median 27 → 22 ÷ 27 − 1 = −18.5%, so below the median.More in the Academy: Lesson cheaper or pricier than usual?
There is currently no comparison of the P/E with its own history (for example too few comparable annual values).
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation.Sign up free
Source: SEC filings and our daily candles
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividend per share
nonepays no dividend
To shareholders (5 years)
858.0M USD100% through repurchases
Share count over 5 years
+5.4%more shares – dilution
What goes back to shareholders
Over 5 years, 858.0M USD went back to shareholders, 100% of it through share repurchases. That is 36% of the free cash flow of those years. This was offset by new shares issued for 290.0M USD (including employee plans).
2016Fiscal year 2016: Dividends paid not available · Share repurchases 249.3M USD · New shares issued (including employee plans) 47.7M USD · Free cash flow 427.3M USD
2017Fiscal year 2017: Dividends paid not available · Share repurchases 251.0M USD · New shares issued (including employee plans) 71.0M USD · Free cash flow 565.0M USD
2018Fiscal year 2018: Dividends paid not available · Share repurchases 201.0M USD · New shares issued (including employee plans) 46.0M USD · Free cash flow 846.0M USD
2019Fiscal year 2019: Dividends paid not available · Share repurchases 324.0M USD · New shares issued (including employee plans) 59.0M USD · Free cash flow 842.0M USD
2020Fiscal year 2020: Dividends paid not available · Share repurchases 736.0M USD · New shares issued (including employee plans) 61.0M USD · Free cash flow 891.0M USD
2021Fiscal year 2021: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 60.0M USD · Free cash flow 337.0M USD
2022Fiscal year 2022: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 63.0M USD · Free cash flow 106.0M USD
2023Fiscal year 2023: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 67.0M USD · Free cash flow 283.0M USD
2024Fiscal year 2024: Dividends paid not available · Share repurchases 116.0M USD · New shares issued (including employee plans) 56.0M USD · Free cash flow 709.0M USD
2025Fiscal year 2025: Dividends paid not available · Share repurchases 742.0M USD · New shares issued (including employee plans) 44.0M USD · Free cash flow 931.0M USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.Log in
Sector comparison
Illumina, Inc. next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
Sector comparison ILMN, sector Health Care; last row: sector median
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light yellow: below sector
+6.0%per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 6.0% per year on average, but more slowly than the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light yellow: below sector
+5.3%per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: +4.1% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 5.3% per year on average, but more slowly than the median company in the sector (+5.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 19.57 USD remained as profit – at least as much as the median company in the sector (13.9%). Five years ago the margin was 20.3%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light green: lower than sector
0.57latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.57 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light red: 3 loss years
7 of 10fiscal years with a profit
What does this mean? In 7 of the last 10 fiscal years the bottom line showed a profit. 3 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
4.3B USD
Revenue vs. prior year
−0.7%
Net income (FY)
850.0M USD
Net income vs. prior year
–
EPS (FY)
5.45 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 28, 2025 · 10-K filed Feb 12, 2026 · Balance sheet Sep 27, 2026 (filed Oct 30, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 28, 2025
4.3B
850.0M
19.6%
5.45
–
–
2024
Dec 29, 2024
4.4B
−1.2B
−28.0%
−7.69
–
–
2023
Dec 31, 2023
4.5B
−1.2B
−25.8%
−7.34
–
–
2022
Jan 1, 2023
4.6B
−4.4B
−96.1%
−28.00
–
–
2021
Jan 2, 2022
4.5B
762.0M
16.8%
5.04
–
–
2020
Jan 3, 2021
3.2B
656.0M
20.3%
4.45
–
–
2019
Dec 29, 2019
3.5B
1.0B
28.3%
6.74
–
–
2018
Dec 30, 2018
3.3B
826.0M
24.8%
5.56
–
–
2017
Dec 31, 2017
2.8B
726.0M
26.4%
4.92
–
–
2016
Jan 1, 2017
2.4B
462.6M
19.3%
3.07
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q3/26
Sep 27, 2026
1.1B
220.0M
19.5%
1.43
–
–
Q2/26
Jun 28, 2026
1.2B
207.0M
17.9%
1.35
–
–
Q1/26
Mar 29, 2026
1.1B
134.0M
12.3%
0.87
–
–
Q4/25*
Dec 28, 2025
1.2B
334.0M
28.8%
–
–
–
Q3/25
Sep 28, 2025
1.1B
150.0M
13.8%
0.98
–
–
Q2/25
Jun 29, 2025
1.1B
235.0M
22.2%
1.49
–
–
Q1/25
Mar 30, 2025
1.0B
131.0M
12.6%
0.82
–
–
Q4/24*
Dec 29, 2024
1.1B
186.0M
16.8%
–
–
–
Q3/24
Sep 29, 2024
1.1B
705.0M
65.3%
4.42
–
–
Q2/24
Jun 30, 2024
1.1B
−2.0B
−178.8%
−12.48
–
–
Q1/24
Mar 31, 2024
1.1B
−126.0M
−11.7%
−0.79
–
–
Q4/23*
Dec 31, 2023
1.1B
−176.0M
−15.7%
–
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Insider purchases and sales on the market over 3, 6 and 12 months
Period
Purchases
Sales
Net
3 months
$00 people
$270.2M2 people
−$270.2M
6 months
$00 people
$672.0M5 people
−$672.0M
12 months
$23.6K1 person
$720.6M5 people
−$720.6M
Latest transactions
Nov 11, 2026Meister Keith A.DirectorOpen-market sale1,843 shares · $407.5K · SEC
Nov 11, 2026Meister Keith A.DirectorOpen-market sale4,618 shares · $1.0M · SEC
Nov 11, 2026Meister Keith A.DirectorOpen-market sale12,305 shares · $2.7M · SEC
Nov 11, 2026Meister Keith A.DirectorOpen-market sale23,064 shares · $5.0M · SEC
Nov 11, 2026Meister Keith A.DirectorOpen-market sale8,613 shares · $1.9M · SEC
Nov 11, 2026Meister Keith A.DirectorOpen-market sale5,122 shares · $1.1M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Which superinvestors hold Illumina, Inc.?
Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
Trend score –
We do not calculate a trend score for symbols in the extended universe.
Volatility and trend strength
ADX 14 (trend strength)–
Price change 60 days–
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.